Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer

TP53 is the most frequently mutated or deleted gene in triple negative breast cancer (TNBC). Both the loss of TP53 and the lack of targeted therapy are significantly correlated with poor clinical outcomes, making TNBC the only type of breast cancer that has no approved targeted therapies. Through in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jiangsheng, Liu, Yunhua, Li, Yujing, Wang, Hai, Stewart, Samantha, Van der Jeught, Kevin, Agarwal, Pranay, Zhang, Yuntian, Liu, Sheng, Zhao, Gang, Wan, Jun, Lu, Xiongbin, He, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449187/
https://www.ncbi.nlm.nih.gov/pubmed/30804480
http://dx.doi.org/10.1038/s41565-019-0381-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449187/
https://www.ncbi.nlm.nih.gov/pubmed/30804480
http://dx.doi.org/10.1038/s41565-019-0381-6

Ejemplares similares